Health Care/Hospital
Syneron Bio Announces Completion of $150 Million Series B Financing
BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Dechen...
2026-04-03 15:02
3254
VARON Marks Earth Hour 2026 with a Call for Sustainable Respiratory Care and Climate Action
NEW YORK, March 27, 2026 /PRNewswire/ -- In observance of Earth Hour 2026, VARON
2026-04-03 13:40
2762
Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis
WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A antibody, in patients with ulcerative c...
2026-04-02 19:00
3747
StairMed Secures RMB 500 Million Financing Led by Alibaba, Joined by Tencent
SHANGHAI, April 2, 2026 /PRNewswire/ -- Shanghai StairMed Technology Co., Ltd. ("StairMed" or "the Company") recently announced the closing of a strategic financing round totaling RMB 500 million. The round was led by Alibaba, with strong continued participation from existing shareholders includi...
2026-04-02 14:41
3094
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions
* Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions. * The presentation will be delivered by W. Timothy Garvey, MD, a g...
2026-04-02 12:04
4713
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
SHANGHAI, April 1, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. The evening, co-hosted by Founding Platinum Sponsor Wilson ...
2026-04-02 08:00
3393
Smartee Introduces Material and Trimline Selection Features to Enhance Aligner Customization
SHANGHAI, April 1, 2026 /PRNewswire/ -- Smartee Denti-Technology today announced the addition of Material Choice and Trimline Selection features to its digital case management system SmarteeCheck. Available immediately at the case approval stage, these updates provide clinicians with greater flex...
2026-04-01 21:16
3527
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases - - BBT001 achieved rapid, deep, a...
2026-04-01 21:00
4865
Sino Biological ProPure™ Endotoxin-Free Proteins: The "Invisible Guardian" of Biopharmaceuticals
HOUSTON, April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, the lipopolysaccharide (LPS) from gram-negative bacteria. Ev...
2026-04-01 18:30
2557
Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan Drug Desig...
2026-04-01 10:02
3442
Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland
* Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters * Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support * Plans further investments to add capabilities and strengthe...
2026-03-31 22:00
3928
NUH LAUNCHES INNOVATION HUB TO ACCELERATE SMART SOLUTIONS AND TRANSFORM HEALTHCARE DELIVERY
By driving a robust culture of innovation, the hub will provide a collaborative space to test and scale solutions with partners, speeding progress in patient care and operations SINGAPORE, March 31, 2026 /PRNewswire/ -- The National University Hospital (NUH) has launched the NUH Innovation Hub, ...
2026-03-31 21:31
3260
BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agree...
2026-03-31 21:00
3279
Co-PSMA data published in the European Urology journal
SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results fro...
2026-03-31 20:58
2383
Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading
Public offering oversubscribed 1,073 times as medical imaging AI company debuts on HKEX HANGZHOU, China, March 31, 2026 /PRNewswire/ -- Hangzhou Diagens Biotechnology Co., Ltd. (HKEX: 02526) today began trading on the Main Board of The Stock Exchange of Hong Kong. Shares closed at HK$202.60, up ...
2026-03-31 18:34
4107
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's...
2026-03-31 17:40
2506
Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children
SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced thatthe U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-...
2026-03-31 14:10
2825
NAVER D2SF Makes Follow-On Investment in Nuvilab, AI Nutrition Analytics Startup
SEONGNAM, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Nuvilab, an AI-powered nutrition analytics healthcare startup. Following its seed investment shortly after the company's founding in 2021, NAVER D2SF ha...
2026-03-31 08:30
3300
NAVER D2SF Makes Follow-On Investment in Soundable Health, an AI-Driven Health Tech Startup Scaling in the U.S. Market
SEOUL, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Soundable Health, a health tech startup leveraging AI-powered acoustic analysis to enable clinical-grade diagnostics through everyday devices. Having parti...
2026-03-31 08:30
3832
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
* OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab * New anatomic data demonstrates OLN324 achieves faster, greater, and more durable re...
2026-03-31 08:00
3570
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 312 media titles]
2026-04-16 17:15
Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
iQIYI to Open Its First Central China Theme Park in Wuhan, Continuing to Bring IP Value Beyond the Screen
[Picked up by 292 media titles]
2026-04-10 11:38
Most Read
NYSE Content Update: Sourcery Founder Molly O'Shea Joins as a Media Partner
2026-04-10 21:14
8040
High Templar Tech Limited Files Its Annual Report on Form 20-F
2026-04-10 18:30
7972